Copyright: ©Author(s) 2026.
World J Gastroenterol. Mar 28, 2026; 32(12): 116287
Published online Mar 28, 2026. doi: 10.3748/wjg.v32.i12.116287
Published online Mar 28, 2026. doi: 10.3748/wjg.v32.i12.116287
Figure 3 A nomogram for the risk of interferon therapy beyond 48 weeks in patients with chronic hepatitis B.
HBsAg: Hepatitis B surface antigen; IFN: Interferon.
- Citation: Yan F, Xue XL, Guo Y, Zhang QR, You RR, Shang J, Wu XP, Geng JW, Gao XH, Ye Q, Liang J, Wang XY, Zeng JY, Chen J, Lin YC, Chen XY, Du Q, Yin WL, Liu L, Wang F, Xu BG, Zhang WH, Xiang HL. Baseline hepatitis B surface antigen and cirrhosis predict extended interferon therapy in chronic hepatitis B: A retrospective study. World J Gastroenterol 2026; 32(12): 116287
- URL: https://www.wjgnet.com/1007-9327/full/v32/i12/116287.htm
- DOI: https://dx.doi.org/10.3748/wjg.v32.i12.116287